The Phoenix Atherectomy System combines the benefits of existing atherectomy systems to deliver a unique and effective atherectomy option to help physicians tailor the treatment approach for each patient. [1,2] Designed to cut, capture, and clear the diseased tissue with just one insertion, Phoenix can treat a broad range of tissue types, from soft plaque to calcified arteries, both above and below the knee. [2]*
By clicking on the link, you will be leaving the official Royal Philips ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
For immediate technical support, please use the phone numbers below.
Philips Saudi Arabia (Al-Khobar)
Tel: +96638870227
Hotline: +966 1 462 8 060
Philips Saudi Arabia (Jeddah)
Tel: +966 2 610 5505
Hotline: +96638870227
Media Gallery
Features
Deliverability
Safe
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
Safe
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
Safe
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
Front cutter
Simple*
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Simple*
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Simple*
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Versatility
Effective [2]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Effective [2]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Effective [2]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Ease of use
Proven success [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
Proven success [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
Proven success [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
Safe
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
Safe
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
The front cutter clears tissue in a way that may help reduce potential trauma to the vessel, demonstrating a 1.9% perforation rate and a 0.9% dissection rate. [3]† The design of the Phoenix cutter head allows debulked material to be continuously captured, showing a <1% distal embolization rate and 0% use of distal protection. [3] ‡
Front cutter
Simple*
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Simple*
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Simple*
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Phoenix is designed for single insertion, featuring a low-profile front cutting element at the distal tip for direct lesion access. Material is shaved and continuously captured within the catheter and cleared via an Archimedes screw. This cut, capture, and clear mechanism eliminates the need to remove the device during the procedure.* The system is powered by a motorized handle, requiring no capital equipment or additional procedural accessories.
Versatility
Effective [2]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Effective [2]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Effective [2]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Data from the EASE trial confirms Phoenix’s ability to effectively treat a broad range of tissue types, from soft plaque to calcified arteries, for lesions both above and below the knee. The effectiveness endpoint set in the EASE trial was exceeded, and a<1% clinically driven target lesion revascularization (TLR) was achieved through 30 days. [3]
Ease of use
Proven success [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
Proven success [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
Proven success [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
Across seven studies and over 1,000 patients, Phoenix demonstrated a procedural success rate of 90-100% with no filter device and a <1% symptomatic distal embolization. [3-9]
Always read the label and follow the directions for use.
Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device. Products subject to country availability. Please contact your local sales representative. Philips reserves the right to change product specifications without prior notification.
Phoenix atherectomy system is distributed by InterMed in New Zealand.
*The Phoenix Atherectomy 1.5 mm Tracking Catheter is indicated for vessels 2.0 mm in diameter or above. The Phoenix Atherectomy 1.8 mm Tracking Catheter is indicated for vessels 2.5 mm in diameter or above. The Phoenix Atherectomy 2.2 mm Tracking, 2.2 mm Pre-Deflected, and 2.4 mm Pre-deflected Catheters are indicated for vessels 3.0 mm in diameter or above. 1.5 mm, 1.8 mm, and 2.2 mm Tracking Catheters and 2.2 mm Pre-deflected Catheter are indicated for femoral, popliteal, or distal arteries located below the knee. The 2.4 mm Pre-deflected Catheter is indicated for femoral and popliteal arteries only. Refer to product IFU for detailed instructions.
† Grade C or greater
‡ Requiring intervention
1. Rotational atherectomy refers to the Phoenix family of products. 2.4mm deflecting catheter and 2.2 mm auto-deflected catheter have directional cutting ability.
2. Schöfthaler C, Troisi N, Torsello G, Jehn A, Lichtenberg M, Karcher JC, Stavroulakis K, D’Oria M, Saratzis A, Zayed H, Andrassy M, Korosoglou G. Safety and effectiveness of the phoenix atherectomy device for endovascular treatment of common femoral and popliteal arteries: Results of the EN-MOBILE trial. Vasc Med. 2024 Mar 17:1358863X241231943. Doi: 10.1177/1358863X241231943. Epub ahead of print. PMID: 38493349.
3. Davis, Thomas et al., Safety and effectiveness of the Phoenix Atherectomy System in lower extremity arteries: Early and midterm outcomes from the prospective multicenter EASE study. Vascular. September 27, 2017, DOI: 10.1177/1708538117712383. Target lesion locations: ATK (48%) and BTK (52%). Technical success rate was 95.1% (performance goal was 86%). The 2.2 pre-deflected and the 1.5 tracking catheters were determined to be substantially equivalent to the devices studied in the EASE trial.
5. Giusca S, Safety, effectiveness and mid-term follow-up in 136 consecutive patients with moderate to severely calcified lesions undergoing phoenix atherectomy, Heart and Vessels, Oct 2020
6. Janas A, Comparison of long-term outcomes after directional versus rotational atherectomy in peripheral artery disease, Adv Interv Cardiol 2020; 16, 1 (59): 76–81
7. Giusca S, Hagstotz S, Lichtenberg M, Heinrich U, Eisenbach C, Andrassy M, Korosoglou G. Phoenix atherectomy for patients with peripheral artery disease. EuroIntervention. 2022 Aug 5;18(5):e432-e442. doi: 10.4244/EIJ-D-21-01070. PMID: 35389346.
8. Shishehbor et al. Acute Real-World Outcomes From the Phoenix Post-Approval Registry. J Invasive Cardiol. 2022 Jan;34(1):E1-E7. Epub 2021 Dec 19
9. Kumarasamy A, Gombert A, Krabbe J, Ruprecht O, Jacobs MJ, Krabbe H. Assessment of Feasibility and Patency of below the Knee Atherectomy Using the 1.5 mm Phoenix Catheter-A Retrospective Study. Medicina (Kaunas). 2022 Nov 3;58(11):1594. doi: 10.3390/medicina58111594. PMID: 36363551; PMCID: PMC9699591.
10. Monitor flow of excised material into the disposal reservoir during operation of the Catheter. If flow of excised material ceases during the procedure, this is a sign that the Catheter drive system (cutter, torque shaft, or Handle motor drive) may not be operating properly.
11. Case study results are not predictive. Results in other cases may vary.
12. Center mass cutting device when the guidewire is centered.
By clicking on the link, you will be leaving the official Royal Philips ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
![Effective [2]](https://images.philips.com/is/image/philipsconsumer/4b0bb6604cbd49028cc9b46500e59756?wid=452&hei=255&$jpglarge$&fit=crop)
![Proven success [3-9]](https://images.philips.com/is/image/philipsconsumer/8f56575b01c44305a197b48d00fd7ff8?wid=452&hei=255&$jpglarge$&fit=crop)
